Practice Guidelines for Reversal of New and Old Anticoagulants

Disease-a-Month

Volumn 58, Issue 8, 2012, Pages 448-461

  Hartman, S Kate ^a   Teruya, Jun ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

APIXABAN; ARGATROBAN; BLOOD CLOTTING FACTOR 9 COMPLEX; DABIGATRAN; FONDAPARINUX; FRESH FROZEN PLASMA; HEPARIN; HIRUDIN; HIRULOG; LEPIRUDIN; LOW MOLECULAR WEIGHT HEPARIN; PROTAMINE SULFATE; PROTHROMBIN COMPLEX; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RECOMBINANT BLOOD CLOTTING FACTOR 9; RIVAROXABAN; VITAMIN K GROUP; WARFARIN;

ACUTE CORONARY SYNDROME; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; COIL EMBOLIZATION; DRUG HALF LIFE; DRUG MEGADOSE; DRUG MONITORING; GENETIC POLYMORPHISM; HEMOPHILIA A; HEMOPHILIA B; HEMOSTASIS; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; KIDNEY DYSFUNCTION; LIVER DISEASE; PARTIAL THROMBOPLASTIN TIME; PRACTICE GUIDELINE; PREGNANT WOMAN; PROTHROMBIN TIME; THROMBOEMBOLISM; THROMBOGENESIS;

ANTICOAGULANTS; BLOOD COAGULATION; BLOOD COAGULATION TESTS; DRUG MONITORING; DRUG TOXICITY; HEMORRHAGE; HEPARIN; HUMANS; POLYSACCHARIDES; PRACTICE GUIDELINES AS TOPIC; PREOPERATIVE CARE; THROMBOSIS; WARFARIN;

EID: 84864088691     PISSN: 00115029     EISSN: 15578194     Source Type: Journal    
DOI: 10.1016/j.disamonth.2012.04.003     Document Type: Article

References (58)

1. th edition). Chest 2012, 141(Suppl 2):e44S-e88S.
2. Koutrouvelis A., Abouleish A., Indrikovs A., et al. Case scenario: emergency reversal of oral anticoagulation. Anesthesiology 2010, 113(5):1192-1197.
3. Hirsh J., Raschke R. Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004, 126(Suppl 3):188S-203S.
4. Cervera A., Amaro S., Chamorro A. Oral anticoagulant-associated intracerebral hemorrhage. J Neurol 2012, 259(2):212-224.
5. Schulman S., Beyth R.J., Kearon C., et al. Hemorrhagic complications of anticoagulant and thrombolytic treatment: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008, 133(Suppl 6):257S-298S.
6. Dager W.E., Kiser T.H. Systemic anticoagulation considerations in chronic kidney disease. Adv Chronic Kidney Dis 2010, 17(5):420-427.
7. Dinwoodey D.L., Ansell J.E. Heparins, low-molecular-weight heparins, and pentasaccharides: use in the older patient. Cardiol Clin 2008, 26(2):145-155.
8. th edition). Chest 2012, 141(Suppl 2):e24S-e43S.
9. th edition). Chest 2012, 141(Suppl 2):e152S-e184S.
10. Kuruvilla M., Gurk-Turner C. A review of warfarin dosing and monitoring. Proc (Bayl Univ Med Cent) 2001, 14(3):305-306.
11. Levi M., Eerenberg E., Kamphuisen P.W. Bleeding risk and reversal strategies for old and new anticoagulants and antiplatelet agents. J Thromb Haemost 2011, 9(9):1705-1712.
12. Haas S. New oral Xa and IIa inhibitors: updates on clinical trial results. J Thromb Thrombolysis 2008, 25(1):52-60.
13. Levi M., Eerenberg E.S., Kampuisen P.W. Anticoagulants. Old and new. Hamostaseologie 2011, 20:31(4):229-235.
14. Weitz J.I., Hirsh J., Samama M.M. New antithrombotic drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition). Chest 2008, 133:234S-256S.
15. Boneu B., de Moerloose P. How and when to monitor a patient treated with low molecular weight heparin. Semin Thromb Hemost 2001, 27(5):519-522.
16. Samama M.M., Guinet C. Laboratory assessment of new anticoagulants. Clin Chem Lab Med 2011, 49(5):761-772.
17. Makris M., Van Veen J.J. Three or four factor prothrombin complex concentrate for emergency anticoagulation reversal?. Blood Transfus 2011, 9(2):117-119.
18. Chong C.T., Lew T.W., Kuperan P., et al. Rapid reversal of coagulopathy in warfarin-related intracranial haemorrhages with prothrombin complex concentrates. Anaesthesiol Intensive Care 2010, 38(3):474-480.
19. Luporsi P., Chopard R., Janin S., et al. Use of recombinant factor VIIa (NovoSeven(®) in 8 patients with ongoing life-threatening bleeding treated with fondaparinux. Acute Card Care 2011, 13(2):93-98.
20. Majeed A., Eelde A., Agren A., et al. Thromboembolic safety and efficacy of prothrombin complex concentrates in the emergency reversal of warfarin coagulopathy. Thromb Res 2012, 129(2):146-151.
21. Yasaka M., Sakata T., Naritomi H., et al. Optimal dose of prothrombin complex concentrate for acute reversal of oral anticoagulation. Thromb Res 2005, 115(6):455-459.
22. Gravlee G., Davis R., Kurusz M. Anticoagulation for cardiopulmonary bypass. Cardiopulmonary Bypass: Principles and Practice 2008, Lippincott, Williams, & Wilkins, Philadelphia, PA, Chapter 22. B. Brown, N. Dernoski (Eds.).
23. Petitou M., Duchaussoy P., Herbert J.M., et al. The synthetic pentasaccharide fondaparinux: first in the class of antithrombotic agents that selectively inhibit coagulation factor Xa. Semin Thromb Hemost 2002, 28(4):393-402.
24. Walenga J.M., Hoppensteadt D.A. Monitoring the new antithrombotic drugs. Semin Thromb Hemost 2004, 30(6):683-695.
25. Lisman T., Bijsterveld N.R., Adelmeijer J., et al. Recombinant factor VIIa reverses the in vitro and ex vivo anticoagulant and profibrinolytic effects of fondaparinux. J Thromb Haemost 2003, 1:2368-2373.
26. Bijsterveld N.R., Moons A.H., Boekholdt S.M., et al. Ability of recombinant factor VIIa to reverse the anticoagulant effect of the pentasaccharide fondaparinux in healthy volunteers. Circulation 2002, 106:2550-2554.
27. Bordes J., Asencio Y., Kenane N., et al. Recombinant activated factor VII for acute subdural haematoma in an elderly patient taking fondaparinux. Br J Anaesth 2008, 101(4):575-576.
28. Pai S., Payne C. Life threatening retroperitoneal haemorrhage due to therapeutic fondaparinux. BMJ Case Rep 2009, 2009.
29. Nutescu E., Chuatrisorn I., Hellenbart E. Drug and dietary interactions of warfarin and novel oral anticoagulants: an update. J Thromb Thrombolysis 2011, 31(3):326-343.
30. Baker P., Gleghorn A., Tripp T., et al. Reversal of asymptomatic over-anticoagulation by orally administered vitamin K. Br J Haematol 2006, 133(3):331-336.
31. Vigué B. Bench-to-bedside review: optimising emergency reversal of vitamin K antagonists in severe haemorrhage-from theory to practice. Crit Care 2009, 13(2):209.
32. Dentali F., Marchesi C., Pierfranceschi M.G., et al. Safety of prothrombin complex concentrates for rapid anticoagulation reversal of vitamin K antagonists. A meta-analysis. Thromb Haemost 2011, 106(3):429-438.
33. Technical Manual 2011, editor, AABB (American Association of Blood Banks)AABB (American Association of Blood Banks), AABB, Bethesda, MD. 17th edn.
34. Leissinger C.A., Blatt P.M., Hoots W.K., et al. Role of prothrombin complex concentrates in reversing warfarin anticoagulation: a review of the literature. Am J Hematol 2008, 83:137-143.
35. Logan A.C., Yank V., Stafford R.S. Off-label use of recombinant factor VIIa in U.S. hospitals: analysis of hospital records. Ann Intern Med 2011, 154(8):516-522.
36. Demeyere R., Gillardin S., Arnout J., et al. Comparison of fresh frozen plasma and prothrombin complex concentrate for the reversal of oral anticoagulants in patients undergoing cardiopulmonary bypass surgery: a randomized study. Vox Sang 2010, 99:251-260.
37. Martinowitz U., Michaelson M. Israeli Multidisciplinary rFVIIa Task Force. Guidelines for the use of recombinant activated factor VII (rFVIIa) in uncontrolled bleeding: a report by the Israeli multidisciplinary rFVIIa task Force. J Thromb Haemost 2005, 3(4):640-648.
38. Morris T.A. New synthetic antithrombotic agents for venous thromboembolism: pentasaccharides, direct thrombin inhibitors, direct Xa inhibitors. Clin Chest Med 2010, 31:707-718.
39. Blommel M.L., Blommel A.L. Dabigatran etexilate: A novel oral direct thrombin inhibitor. Am J Health Syst Pharm 2011, 68(16):1506-1519.
40. Van Ryn J., Stangier J., Haertter S., et al. Dabigatran etexilate-a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost 2010, 103(6):1116-1127.
41. Di Nisio M., Middeldorp S., Büller H.R. Direct thrombin inhibitors. N Engl J Med 2005, 353(10):1028-1040.
42. Bendel S.D., Bona R., Baker W.L. Dabigatran: an oral direct thrombin inhibitor for use in atrial fibrillation. Adv Ther 2011, 28(6):460-472.
43. Legrand M., Mateo J., Aribaud A., et al. The use of dabigatran in elderly patients. Arch Intern Med 2011, 171(14):1285-1286.
44. Eerenberg E.S., Kamphuisen P.W., Sijpkens M.K., et al. Reversal of Rivaroxaban and Dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation 2011, 124:1573-1579.
45. Logan A.C., Goodnough L.T. Recombinant factor VIIa: an assessment of evidence regarding its efficacy and safety in the off-label setting. Hematology Am Soc Hematol Educ Program 2010, 2010:153-159.
46. Levi M., Levy J.H., Andersen H.F., et al. Safety of recombinant activated factor VII in randomized clinical trials. N Engl J Med 2010, 363(19):1791-1800.
47. Skolnick B.E., Mathews D.R., Khutoryansky N.M., et al. Exploratory study on the reversal of warfarin with rFVIIa in healthy subjects. Blood 2010, 116:693-701.
48. Hsia C.C., Chin-Yee I.H., McAlister V.C. Use of recombinant activated factor VII in patients without hemophilia: a meta-analysis of randomized control trials. Ann Surg 2008, 248:61-68.
49. Mayer S.A., Brun N.C., Begtrup K., et al. Recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med 2005, 352:777-785.
50. Mayer S.A., Brun N.C., Broderick J., et al. Safety and feasibility of recombinant factor VIIa for acute intracerebral hemorrhage. Stroke 2005, 36:74-79.
51. Herring S. Grifols' factor IX concentrates: new findings in biochemical characteristics and safety profiles. Haemophilia 2010, 16(Suppl 6):3-8.
52. Samama C.M. Prothrombin complex concentrates: a brief review. Eur J Anaesthesiol 2008, 25(10):784-789.
53. Smith S.A., Morrissey J.H. Polyphosphate as a general procoagulant agent. J Thromb Haemost 2008, 6(10):1750-1756.
54. Caen J., Wu Q. Hageman factor, platelets and polyphosphates: early history and recent connection. J Thromb Haemost 2010, 8(8):1670-1674.
55. Lu G., DeGuzman F., Hollenbach S., et al. Reversal of rivaroxaban mediated anticoagulation in animal models by a recombinant antidote protein (r-antidote, PRT06445). Presented at European Society of Cardiology Congress August 2011.
56. Bianchini E.P., Fazavana J., Picard V., et al. Development of a recombinant antithrombin variant as a potent antidote to fondaparinux and other heparin derivatives. Blood 2011, 117(6):2054-2060.
57. Donovan J.L., Drake J.A., Whittaker P., et al. Pharmacy-managed anticoagulation: assessment of in-hospital efficacy and evaluation of financial impact and community acceptance. J Thromb Thrombolysis 2006, 22(1):23-30.
58. Schillig J., Kaatz S., Hudson M., et al. Clinical and safety impact of an inpatient pharmacist-directed anticoagulation service. J Hosp Med 2011, 6(6):322-328.